Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Huster

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The New England Journal of Medicine|December 4, 1997
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal womenP D Delmas, N H Bjarnason, B H Mitlak, et al.
Diabetes, Obesity & Metabolism|May 15, 2015
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 studyT C Blevins, D Dahl, J Rosenstock, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Effect of premixed nph and regular insulin on glucose control and health-related quality of life in patients with type 2 diabetes mellitusJ A Davidson, D Einhorn, P Allweiss, et al.
Diabetes, Obesity & Metabolism|October 6, 2015
Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitusL L Ilag, M A Deeg, T Costigan, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The New England Journal of Medicine|December 4, 1997
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal womenP D Delmas, N H Bjarnason, B H Mitlak, et al.
Diabetes, Obesity & Metabolism|May 15, 2015
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 studyT C Blevins, D Dahl, J Rosenstock, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 15, 2004
Effect of premixed nph and regular insulin on glucose control and health-related quality of life in patients with type 2 diabetes mellitusJ A Davidson, D Einhorn, P Allweiss, et al.
Diabetes, Obesity & Metabolism|October 6, 2015
Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitusL L Ilag, M A Deeg, T Costigan, et al.
Pageof 3